{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "65d3bc71",
   "metadata": {},
   "source": [
    "# Machine learning approch"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "a7b1ecd9",
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk.corpus import stopwords\n",
    "import re\n",
    "import pandas as pd\n",
    "df = pd.read_csv('/home/hrishikeshkanojiya/Desktop/Cuad_labels.csv')\n",
    "from sklearn.feature_extraction.text import CountVectorizer, TfidfVectorizer\n",
    "from sklearn.metrics import accuracy_score"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "6e2f24a9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label Name</th>\n",
       "      <th>title</th>\n",
       "      <th>Context</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Distributor Agreement</td>\n",
       "      <td>LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...</td>\n",
       "      <td>EXHIBIT 10.6\\n\\n                              ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Promotion Agreement</td>\n",
       "      <td>WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...</td>\n",
       "      <td>Exhibit 10.26    CONFIDENTIAL TREATMENT HAS BE...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Supply Agreement</td>\n",
       "      <td>LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...</td>\n",
       "      <td>Exhibit 10.16 SUPPLY CONTRACT Contract No: Dat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Hosting Agreement</td>\n",
       "      <td>CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...</td>\n",
       "      <td>1                                             ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Joint Venture Agreemen</td>\n",
       "      <td>NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT</td>\n",
       "      <td>Exhibit 1\\n\\nJOINT FILING AGREEMENT\\n\\nThe und...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               Label Name                                              title  \\\n",
       "0   Distributor Agreement  LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...   \n",
       "1     Promotion Agreement  WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...   \n",
       "2        Supply Agreement  LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...   \n",
       "3       Hosting Agreement  CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...   \n",
       "4  Joint Venture Agreemen   NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT   \n",
       "\n",
       "                                             Context  \n",
       "0  EXHIBIT 10.6\\n\\n                              ...  \n",
       "1  Exhibit 10.26    CONFIDENTIAL TREATMENT HAS BE...  \n",
       "2  Exhibit 10.16 SUPPLY CONTRACT Contract No: Dat...  \n",
       "3  1                                             ...  \n",
       "4  Exhibit 1\\n\\nJOINT FILING AGREEMENT\\n\\nThe und...  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "8ee1e03e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "26"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df['Label Name'].value_counts())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "ea1cb696",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Distributor Agreement', 'Promotion Agreement', 'Supply Agreement',\n",
       "       'Hosting Agreement', 'Joint Venture Agreemen',\n",
       "       'Endorsement Agreement', 'Consulting Agreement',\n",
       "       'Marketing Agreement', 'Strategic Alliance Agreement',\n",
       "       'Sponsorship Agreement', 'Franchise Agreement', 'IP Agreement',\n",
       "       'Service Agreement', 'Agency Agreement', 'Maintenance Agreement',\n",
       "       'License Agreement', 'Cooperation Agreement',\n",
       "       'Collaboration/Cooperation Agreement', 'Reseller Agreement',\n",
       "       'Outsourcing Agreement', 'Co-Branding Agreement',\n",
       "       'Affiliate Agreement', 'Development Agreement',\n",
       "       'Manufacturing Agreement', 'Transportation Agreement',\n",
       "       'Non-Compete/No-Solicit/Non-Disparagement Agreement'], dtype=object)"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Label Name'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "7e28b35e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Label Name    0\n",
       "title         0\n",
       "Context       0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "b9d1b960",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(510, 3)"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "7aec7391",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop_duplicates(inplace = True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "81969761",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(510, 3)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "4e5d0c15",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3361861"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['Context'].apply(lambda x: len(x.split(' '))).sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "4c9786f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "special_character_remover = re.compile('[/(){}\\[\\]\\|@,;]')\n",
    "extra_symbol_remover = re.compile('[^0-9a-z #+_]')\n",
    "STOPWORDS = set(stopwords.words('english'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "5f96791d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'exhibit 102______________________________________________________________________________copromotion agreementby betweendova pharmaceuticals incandvaleant pharmaceuticals north america llcseptember 26 2018______________________________________________________________________________confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018table contentspagearticle 1 definitions 1article 2 rights obligations 821 engagement grant rights 822 retention rights 923 noncompetition nonsolicitation 924 dova trademarks copyrights 10article 3 joint steering committee 1131 formation jsc 1132 meetings minutes 1133 purpose jsc 1134 decision making 1335 marketing subcommittee 13article 4 valeant activities product 1441 valeant activities 1442 detailing 1543 compliance applicable law 1744 field force personnel training product materials 1945 provisions related field force personnel 2146 responsibility valeant activity costs expenses 2247 data sharing 22article 5 regulatory safety surveillance commercial matters 2351 dova responsibility 2352 valeant involvement 2353 inspections 2354 pharmacovigilance 2455 unsolicited requests medical information 2456 recalls market withdrawals 2557 certain reporting responsibilities 2558 booking sales revenues 2559 returns 25source dova pharmaceuticals inc 10q 11 8 2018iconfidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018table contents continued 510 manufacturing distribution marketing 25article 6 financial provisions 2661 promotion fee 2662 milestone payment 2763 reports payments 2764 taxes 2865 determination specialty 29article 7 audit rights 3071 recordkeeping 3072 valeant rights 3073 dova rights 31article 8 intellectual property 3281 ownership intellectual property 3282 title trademarks copyrights 3283 protection trademarks copyrights 3284 disclosure knowhow 33article 9 confidentiality 3391 confidential information 3392 public announcements 34article 10 representations warranties additional covenants 35101 representations warranties dova 35102 representations warranties valeant 37103 disclaimer warranty 38104 additional covenants 39article 11 indemnification limitations liability 39111 indemnification dova 39112 indemnification valeant 39113 indemnification procedures 40114 limitation liability 40115 insurance 40article 12 term termination 41121 term 41122 early termination cause 41source dova pharmaceuticals inc 10q 11 8 2018123 early termination 42124 effects termination 42125 tail period 42iiconfidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018table contents continued 126 survival 43article 13 miscellaneous 43131 force majeure 43132 assignment 43133 severability 44134 notices 44135 governing law 45136 dispute resolution 45137 waiver jury trial 45138 entire agreement amendments 46139 headings 461310 independent contractors 461311 third party beneficiaries 461312 waiver 461313 cumulative remedies 461314 waiver rule construction 461315 use names 461316 actions documents 471317 certain conventions 471318 counterparts 47iiiconfidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018copromotion agreementthis copromotion agreement agreement entered dated september 26 2018 effective date dova pharmaceuticals inc delaware corporation dova valeant pharmaceuticals north america llc delaware limited liability company valeant dova valeant referred individually party together partiesrecitalswhereas dova developed rights market sell product defined territory whereas parties believe would mutually beneficial collaborate promotional activities product accordingly dova desires valeant conduct certain promotional activities valeant desires conduct activities product territory therefore consideration following mutual promises obligations good valuable consideration adequacy sufficiency hereby acknowledged parties agree followsconfidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018article 1 definitions11 act shall mean federal food drug cosmetic act 21 usc 301 et seq may amended time time regulations promulgated thereunder12 adverse event shall mean untoward medical occurrence patient clinical investigation subject administered product necessarily causal relationship treatment product used adverse event include unfavorable unintended sign including abnormal laboratory finding symptom disease temporally associated use product whether related product preexisting condition worsened severity administration product would considered adverse event13 affiliate shall mean respect person person directly indirectly controls controlled common control person person shall deemed control another person person possesses power direct cause direction management business policies person whether ownership fifty percent 50 lesser percentage maximum allowed owned foreign corporation particular jurisdiction voting securities person contract otherwise14 agreement shall meaning set forth preamble agreement15 alliance managers shall meaning set forth section 41416 alternate product shall mean pharmaceutical product commercialized valeant affiliates territory part salix business segment valeants parent company bausch health companies inc event business segments restructured part salix business unit product complementary product regard target professionals specialty17 applicable laws shall mean applicable statutes ordinances regulations codes rules orders kind whatsoever governmental authority territory pertaining activities obligations contemplated agreement including applicable act generic drug enforcement act 1992 21 usc 335a et seq anti kickback statute 42 usc 1320a7b et seq health insurance portability accountability act 1996 federal false claims act 31 usc 37293733 applicable state false claims acts physician payments sunshine act code department health human services office inspector general compliance program guidance pharmaceutical manufacturers released april 2003 antifraud abuse amendment social security act american medical association guidelines gifts physicians generally accepted standards good clinical practices adopted current fda regulations well state laws regulations impacting promotion pharmaceutical products ii governing provision meals gifts medical professionals including pharmacists iii governing consumer2confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018protection deceptive trade practices including state antikickback fraud abuse related laws amended time time18 business day means day week excluding saturday sunday day banking institutions new york new york usa closed19 calendar quarter shall mean successive period three 3 calendar months commencing january 1 april 1 july 1 october 1 except first calendar quarter term shall commence effective date end day immediately prior first occur january 1 april 1 july 1 october 1 effective date last calendar quarter shall end last day term110 calendar year shall mean successive period twelve 12 months commencing january 1 ending december 31 except first calendar year term shall commence effective date end december 31 year effective date occurs last calendar year term shall commence january 1 year term ends end last day term111 claims shall mean charges complaints actions suits proceedings hearings investigations claims demands judgments orders decrees stipulations injunctions case third party including governmental authority 112 code shall mean code interactions healthcare professionals promulgated pharmaceutical research manufacturers america phrma bio may amended113 compensation report shall meaning set forth section 422 b 114 compliance manager shall meaning set forth section 439115 compliance report shall meaning set forth section 422 c 116 confidential information shall mean secret confidential nonpublic proprietary knowhow whether provided written oral graphic video computer form provided behalf one party party pursuant agreement including information relating disclosing partys existing proposed research development efforts promotional efforts regulatory matters patent applications business materials made available disclosing party general public information related agreement disclosed behalf party affiliate party affiliate pursuant confidentiality agreement shall deemed partys confidential information disclosed hereunder purposes clarity dovas confidential information shall include product materials unless made available dova general public including valeant ii terms agreement shall considered confidential information parties117 confidentiality agreement shall meaning set forth section 9113confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018118 designated product shall mean specific pharmaceutical product marketed valeant agreed writing parties prior effective date119 detail shall mean product presentation facetoface sales call target professional sales representative presentation products attributes benefits prescribing information safety information orally presented use field territory neither edetails presentations made conventions exhibit booths sample drop educational programs speaker meetings similar gatherings shall constitute detail120 detail report shall meaning set forth section 422121 dispute shall meaning set forth section 1361122 dollar shall mean united states dollar123 dova trademarks copyrights shall mean logos trade dress slogans domain names housemarks dova affiliates may appear product materials product labeling case may updated time time dova124 dovas third party data source shall mean data source selected dova dova enters agreement cost125 effective date shall meaning set forth preamble agreement126 fda shall mean united states food drug administration successor agency performing comparable functions127 field shall mean treatment thrombocytopenia adult patients chronic liver disease scheduled undergo procedure additional indications product approved territory128 field force personnel shall mean collectively sales representatives members institutional account management team described section 415 engaged detailing product employees valeant engaged valeant activities129 gaap shall mean united states generally accepted accounting principles130 governmental authority shall mean court agency authority department regulatory body instrumentality government country national federal state provincial regional county city political subdivision government supranational organization country member competent binding authority decide mandate regulate enforce otherwise control activities parties contemplated agreement4confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018131 gross net fraction shall mean sku product fraction numerator net sales sku product territory applicable period based grosstonet discounts sales sku product ie sales attributable specialty well sales sku product ii denominator gross sales sku product territory applicable period case determined accordance dovas revenue recognition policies accordance gaap consistent basis quarterly financial reporting purposes reported dovas quarterly filings us securities exchange commission132 indemnified party shall meaning set forth section 113133 indemnifying party shall meaning set forth section 113134 intellectual property shall meaning set forth section 812135 intermediary shall mean wholesaler distributor sells product retail pharmacies nonretail institutions patients dova affiliates entered agreement otherwise arrangements136 inventions shall meaning set forth section 812137 jsc shall meaning set forth section 31138 knowhow shall mean information whether written form including biological chemical pharmacological toxicological medical clinical analytical quality manufacturing research sales marketing information including processes methods procedures techniques plans programs data139 losses shall mean amounts paid payable third parties respect claim including losses damages obligations liabilities fines fees penalties awards judgments interest together documented outof pocket costs expenses including attorneys fees reasonably incurred140 net sales shall mean applicable period aggregate amount without duplication equal specialty pharmacy net sales sku retail net sales sku nonretail net sales sku141 nonretail institution shall mean institution specialty pharmacies retail pharmacies intermediaries dova affiliates intermediaries sells ships units product term shall include group purchasing organizations gpos hospitals clinics long term care facilities outlets member integrated delivery network idn dova affiliates data agreements enables dova track shipments product institution patients based target professional prescribing product142 nonretail net sales shall mean sku product5confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018 number units sku products shipped dova affiliates intermediaries nonretail institutions territory applicable period excluding shipments excess one unit either sku shipped nonretail institutions based initial orders nonretail institutions multiplied ii applicable specialty fraction sku product applicable period multiplied iii applicable wac sku product applicable period multiplied iv gross net fraction sku product applicable period143 party shall meaning set forth preamble agreement144 person shall mean individual corporation partnership limited liability company association jointstock company trust unincorporated organization entity government political subdivision thereof145 product shall mean product approved pursuant new drug application nda 210238 approval may supplemented time time including way supplemental new drug application snda currently marketed doptelet avatrombopag territory shall include authorized generic version product146 product labeling shall mean labels written printed graphic matter upon container wrapper utilized product b written material accompanying product including product package inserts case approved fda147 product materials shall meaning set forth section 441 148 product training materials shall meaning set forth section 441 149 quarterly average sales force size shall meaning set forth section 422150 quarterly minimum details applicable calendar quarter shall mean 151 regulatory approval shall mean necessary approvals licenses registrations authorizations governmental authority case necessary commercialize product territory152 retail pharmacy shall mean outlet dispenses product directly patient retail setting mail order services6confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018153 retail net sales shall mean sku product number units sku product shipped retail pharmacies patients based prescriptions written specialty territory determined data reported data aggregator data source dova enters agreement cost multiplied ii applicable wac sku product applicable period multiplied iii gross net fraction sku product applicable period154 sales representative shall mean individual employed compensated valeant fulltime employee part sales forces engages detailing designated product alternate product case may territory also trained respect product accordance agreement including product labeling use promotional materials deliver details product field territory155 senior officer shall mean respect dova president chief executive officer officers designee respect valeant officers designee time time party may change senior officer giving written notice party156 specialty shall mean target professionals primary secondary specialty designation gastroenterology colorectal surgery proctology excluding target professionals primary secondary specialty designation hepatology including transplant hepatology case determined data reported dovas third party data source subject adjustments determined pursuant process set section 65 ii healthcare professionals nurse physician assistant specialty designations affiliated target professionals described subsection adjusted157 specialty fraction shall mean sku product fraction numerator number units sku product shipped specialty pharmacies retail pharmacies patients based prescriptions written specialty territory determined data reported pursuant agreements dova affiliates specialty pharmacies data aggregators applicable ii denominator number units sku product shipped specialty pharmacies retail pharmacies patients territory namely based prescriptions written specialty outside specialty determined data reported pursuant agreements dova affiliates specialty pharmacies data aggregators applicable 158 specialty pharmacy net sales shall mean sku product7confidential treatment requested portions exhibit copy filed herewith omits information subject confidentiality request omissions designated complete version exhibit filed separately securities exchange commissionsource dova pharmaceuticals inc 10q 11 8 2018 number units sku product shipped specialty pharmacies patients based prescriptions written specialty territory applicable period determined data reported pursuant agreements dova affiliates specialty pharmacies data aggregators applicable andmultiplied ii applicable wac sku product applicable period multiplied iii gross net fraction sku product applicable period159 specialty pharmacy shall mean specialty pharmacies dova affiliates sells ships units product term dova affiliates agreements include data provisions provide separate data agreements enables dova track shipments product specialty pharmacy patients based target professional prescribing product160 tail period shall mean period commencing day last day term ending earlier ii unless terminated early pursuant section 231 agreement161 target professionals shall mean physicians nurse practitioners physician assistants medical professionals territory prescribing authority authorized applicable law territory product162 term shall meaning set forth section 121163 territory shall mean united states america territories possessions164 third party ies shall mean person entity dova valeant respective affiliates165 third party agreements shall mean agreements described schedule 165 hereto166 valeant activities shall mean promotional activities including detailing conducted valeant encourage appropriate use product specialty field territory accordance terms agreement167 valeant property shall meaning set forth section 811168 wac shall mean sku product dovas list price unit sku product wholesalers direct purchasers territory reported wholesale price guides nationally recognized publications drug pricing dataarticle 2 rights obligations21 engagement grant rights term subject terms conditions agreement dova hereby grants valeant right coexclusive basis solely dova affiliates detail promote product specialty territory field conduct valeant activities activities institutional account management team pursuant subject terms section 415 product territory field accordance terms conditions agreement notwithstanding foregoing dova retains reserves right dova affiliates promote product territory including specialty valeant shall rights relating product except specifically set forth agreement without limiting foregoing except set section 415 agreed upon valeant shall right shall conduct valeant activities product outside specialty outside territory use outside field except affiliates valeant valeants rights obligations section 21 nontransferable nonassignable nondelegable except affiliates valeant valeant shall subcontract valeant activities third party including contract sales force obligation valeant pursuant agreement may satisfied met fulfilled whole part valeants sole exclusive option either valeant affiliates valeant guarantees performance actions agreements obligations performed affiliates terms conditions agreement clarity valeant shall license rights hereunder rights sublicense rights hereundersource dova pharmaceuticals inc 10q 11 8 201822 retention rights except respect exclusive rights granted valeant conduct valeant activities product specialty territory field pursuant section 21 agreed upon outside specialty territory field pursuant section 415 dova retains rights product without limiting generality foregoing without limiting dovas retained rights set forth section 21 dova specifically retains following rights valeant affiliates shall rights following except set forth section 22 221 responsibility promoting product outside specialty 222 responsibility manufacture distribution product future development product 223 responsibility decisions regarding regulatory submissions except expressly set forth herein interactions governmental authority including limited fda respect product 224 responsibility final approval product materials content including submission promotional materials fdas office prescription drug promotion respect conduct valeant activities product except expressly set forth herein 225 selling booking sales product and226 responsibility handling safety related activities related product set forth article 5 including submitting safety reports interacting governmental authorities respect thereto initiating managing product recallsfor clarity except provided sections 21 24 valeant shall acquire license intellectual property interest implication otherwise technology knowhow intellectual property owned controlled dova affiliates dova providing technology knowhow intellectual property assistance related thereto valeant use mutual benefit parties expressly contemplated hereby23 noncompetition nonsolicitation231 noncompetition neither valeant affiliates shall directly indirectly territory product provided agreement terminated dova pursuant tail period shall immediately terminated either valeant affiliates directly indirectly territory product tail period notwithstanding foregoing section 231 shall apply products marketed promoted detailed offered sale sold business portion thereof person group persons neither dova affiliates shall directly indirectly notwithstanding foregoing section 231 b shall apply products marketed promoted detailed offered sale sold business portion thereof person group persons 232 nonsolicitation neither valeant dova respective affiliates shall directly indirectly solicit hire employee employee consultant otherwise partys professional personnel direct involvement jsc valeant activities agreement case valeant includes field force personnel dovas commercialization activities product without partys prior written consent notwithstanding anything contrary event shall restrictions set forth section 232 apply 24 dova trademarks copyrights241 valeant shall nonexclusive right use dova trademarks copyrights solely product materials order perform valeant activities solely accordance terms conditions agreement dova shall promptly notify valeant updates changes dova trademarks copyrights product materials valeant shall thereafter solely use updated product materials performing obligations agreement valeant shall promptly notify dova upon becoming aware violation section 241242 valeant shall follow instructions guidelines dova dova provided valeant copies connection use dova trademarks copyrights dova reasonably objects manner dova trademarks copyrights used valeant shall cease use dova trademarks copyrights manner upon written notice dova thereof without limiting foregoing valeant shall also adhere least quality control provisions companies pharmaceutical industry adhere trademarks copyrights cases valeant shall use dova trademarks copyrights necessary trademark copyright applicable designations shall use dova trademarks copyrights manner derogate dovas rights dova trademarks copyrights valeant shall time term knowingly allow done act thing way impair diminish rights dova dova trademarks copyrights goodwill andsource dova pharmaceuticals inc 10q 11 8 2018improved reputation generated valeants use dova trademarks copyrights shall inure benefit dova use dova trademarks copyrights valeant shall cease end term valeant shall rights agreement dova trademarks copyrights except specifically provided herein term valeant contest ownership dova trademarks copyrights validity validity registration therefor term valeant knowingly register use marks including connection domain names confusingly similar dova trademarks copyrightsarticle 3 joint steering committee31 formation jsc soon practicable later twenty 20 days effective date parties shall form joint steering committee jsc whose responsibilities term shall oversee activities set forth section 33 jsc shall consist three 3 representatives party suitable seniority relevant experience expertise enable person address matters falling within purview jsc time time party may change representatives jsc giving written notice party meetings jsc chaired representative dova valeant alternating basis jsc shall determine meeting schedule provided event meetings shall conducted less frequently quarterly teleconference person otherwise agreed parties person meetings shall occur places mutually agreed parties employees consultants either party representatives parties jsc may attend meetings jsc provided attendees shall participate decisionmaking process jsc ii bound obligations confidentiality nondisclosure equivalent set forth article 932 meetings minutes meetings jsc may called either party less thirty 30 days notice term party shall make proposals agenda items shall provide appropriate information respect proposed items least ten 10 days advance applicable meeting provided exigent circumstances requiring input jsc party may provide agenda items party within shorter period time advance meeting may propose specific agenda particular meeting long party consents later addition agenda items absence specific agenda meeting consent unreasonably withheld chairperson shall prepare circulate review approval parties minutes meeting within thirty 30 days meeting party shall bear costs members attend meetings33 purpose jsc purposes jsc shall subject section 34331 provide forum discuss coordinate parties activities agreement 332 provide forum discuss coordinate promotion product territory including outside specialty 333 provide forum discuss product materials understood jsc shall right approve product materials 334 facilitate flow information otherwise promote communications collaboration within among parties relating agreement promotion product 335 discuss planning implementation valeant activities including limited training sales representatives agreed upon activities institutional account management team referred section 415 336 decide acceptable form review discuss detail reports reports net sales 337 decide acceptable form review discuss compensation reports incentive compensation matters described section 413 including applicable adjustments productrelated sales goals targets sales representatives 338 review discuss matters brought attention either partys alliance manager 339 review discuss decide alternate product described section 421 c additional product may detailed valeant described section 421 3310 discuss promotional materials matters described section 441 b 3311 discuss supply distribution issues relating product supply shortages 3312 discuss pricing product provided dova shall sole authority determine pricing product source dova pharmaceuticals inc 10q 11 8 20183313 act first level escalation address disagreements disputes parties 3314 form oversee subcommittee working group furtherance activities contemplated agreement 3315 decide acceptable form review discuss compliance reports and3316 perform responsibilities may mutually agreed upon parties writing time time provided however clarity jsc shall authority amend modify provisions agreement authority waive definitively interpret provisions agreement34 decision making meetings jsc occur least one representative party present meeting party shall one 1 vote jsc use good faith efforts reach consensus matters properly brought jsc reach unanimous consensus issue meeting within period thereafter jsc shall submit writing respective positions parties senior officers parties senior officers shall use good faith efforts resolve promptly matter good faith efforts shall include least one 1 teleconference senior officers within jscs submission matter final decision mutually agreed writing senior officers shall conclusive binding parties senior officers able agree resolution issue within issue first referred valeant shall right conclusively determine matters related valeant activities detailing product including matters relating institutional account manager team incentive compensation sales representatives targeting details provided determination related activities comply terms conditions agreement ii dova shall right conclusively determine matters provided however clarity determination shall amend modify waive provisions agreement definitively interpret provisions agreement35 marketing subcommittee351 promptly effective date jsc shall facilitate formation marketing subcommittee comprised equal number representatives party subcommittee shall meet time time discuss among things number speaker programs product conducted dova calendar year b promotional materials quantities thereof c annual brand plan annual conference strategy352 shall constitute speaker program threshold dova wishes conduct speaker programs calendar year 2018 excess speaker program threshold parties shall meet marketing subcommittee discuss excess speaker programs costs thereof marketing subcommittee unanimously agrees excess speaker programs conducted following costs expenses shared equally parties costs expenses associated conducting excess number speaker programs ii additional incremental costs expenses associated training necessary address number speaker programs speaker program threshold addition parties unanimously agree excess speaker programs conducted condition payment valeant share costs valeant shall right review approve acting reasonably good faith excess speaker programs including respect number speakers approved speak product part speaker programs rates paid speakers speaker programs rules regarding attendees may attend speaker programs including frequency attendance greater certainty valeant agree conduct speaker programs speaker program threshold costs described herein speaker programs conducted dova excess speaker program threshold shall shared parties shall borne solely dova event dova incurs costs expenses valeant responsible section 352 dova may deduct amounts payments due section 63 shall include description thereof applicable report section 63article 4 valeant activities product41 valeant activities411 general valeant shall conduct valeant activities product specialty field thesource dova pharmaceuticals inc 10q 11 8 2018territory accordance agreement412 number sales representatives without limiting generality foregoing continuing throughout remainder term valeant shall maintain least one hundred 100 sales representatives responsibility detail product specialty territory notwithstanding sole remedy dova breach section 412 shall adjustment promotion fee set forth section 612 ii termination right set section 1222413 target incentive compensation addition continuing throughout remainder term valeant shall ensure incentive compensation package sales representatives requires least fifty percent 50 target incentive compensation derived achieving target sales product least quarterly basis parties meet jsc review target incentive compensation actual incentive compensation paid sales representatives discuss good faith appropriate adjustments sales targets goals related product abovementioned fifty percent 50 threshold target incentive compensation intent achieving average actual payout sales representatives 50 incentive compensation relating sales product414 alliance managers party shall appoint person shall oversee interactions parties matters related agreement related agreements parties alliance manager alliance managers shall endeavor ensure clear responsive communication parties effective exchange information shall serve single point contact matters arising agreement alliance managers shall right attend jsc meetings applicable subcommittee meetings nonvoting participants may bring attention jsc applicable subcommittee matters issues either reasonably believes discussed shall responsibilities parties may mutually agree writing party may designate different alliance mangers notice writing party415 institutional account management team upon prior mutual agreement parties writing valeant may maintain team institutional account managers among products promote product territory liver transplant centers large academic institutions purposes section 415 inside outside specialty prior promotion product institutional account managers parties discuss good faith acting reasonably number institutional account managers promote product territory appropriate portion institutional account managers target incentive compensation derived sales product liver transplant centers large academic institutions institutional account managers responsible institutional account managers shall counted purposes determining quarterly average sales force size quarterly minimum details parties agree institutional account managers shall required achieve minimum number details parties agree team may added removed mutual written agreement parties without need amend agreement accordance section 13842 detailing421 detail requirements commencing promptly upon completion training field force personnel engaged detailing product described section 441 condition promotional materials approved delivered valeant shall deploy field force personnel engaged detailing detail product accordance terms agreement subject compliance terms agreement valeant shall responsible discretion acting reasonably determining manner allocates prioritizes details provided allocating details valeant shall take consideration geographic territory frequency calls prescribing levels reasonable considerations except set forth agreement without prior written consent dova unreasonably withheld delayed conditioned valeant shall conduct valeant activities detailing respect product b c beginning valeant may initiate discussions dova upon least notice dova notice shall specify proposed alternate product regarding potential replacement designated product alternate product following notice period parties shall meet jsc discuss good faith acting reasonably period potential replacement designated product alternate product parties agree alternate product parties shall make agreement writing thereafter alternate product shall designated product purposes agreement parties cannot agree alternate product period valeant may give dova written notice alternate product notice designating proposed alternate product alternate product effective alternate product notice designated alternate product shall designated product purposes agreement provided however notwithstanding foregoing dova shall right terminate agreement upon written notice valeant alternate product notice provided alternate product proposed valeant result anticipated existence generic version thesource dova pharmaceuticals inc 10q 11 8 2018designated product decision judgment ruling requirement government authority including fda relating impacting designated product territory material safety concern regarding designated product mandatory recall withdrawal designated product dova shall right terminate agreement pursuant section 421 c e notwithstanding terms section 421 valeant shall right time time term include incentive compensation package sales representatives spiff spiv similar incentive bonus based provided actual maximum payout incentive bonuses exceed aggregate amount equal sales representative calendar quarter spiff spiv similar incentive bonus shall included calculation applicable sales representatives incentive compensation package determining valeants compliance terms section 413422 records reports valeant shall keep accurate complete records consistent pharmaceutical industry standards detail obligations hereunder connection therewith records shall kept longer end calendar year relate ii period time required applicable laws within following end calendar quarter term valeant shall provide dova written report detail report setting quarterly average number sales representatives calendar quarter calculated taking sum number sales representatives employed valeant affiliates incentive compensation packages comply terms section 413 business day calendar quarter divided number business days calendar quarter quarterly average sales force size ii aggregate actual number details product made sales representatives calendar quarter number details broken name target professionals jsc parties shall agree mutually acceptable form detail report b within following end calendar quarter term valeant shall provide dova written report compensation report describes details incentive compensation package sales representative relates product designated product alternate product case may case designated product alternate product details shall limited information regarding portion sales representatives target incentive compensation package derived achieving sales targets goals designated product alternate product shall include sales targets goals designated product alternate product ii actual incentive compensation payouts sales representatives described section 413 jsc parties shall agree mutually acceptable form compensation report c within following end calendar quarter term valeant shall provide dova written report compliance report sets summary valeants compliance monitoring auditing field force personnel engaged detailing monitoring described section 451 b summary compliancerelated disciplinary actions relating field force personnel engaged detailing associated remedial actions summary compliance investigations conducted valeant field force personnel engaged detailing associated outcome fourth calendar quarter summary compliancerelated training including reasonable description training topic received field force personnel engaged detailing calendar year jsc parties shall agree mutually acceptable form compliance report43 compliance applicable law431 conducting valeant activities hereunder valeant shall shall require field force personnel comply respects applicable laws addition dova shall shall require sales representatives comply respects applicable laws connection promotion product territory432 neither valeant field force personnel shall offer pay solicit receive remuneration target professionals order induce referrals purchase product433 performing activities contemplated agreement neither valeant field force personnel shall make payment either directly indirectly money assets government political party officials officials international public organizations candidates public office representatives businesses persons acting behalf foregoing payment would constitute violation applicable law addition valeant shall make payment either directly indirectly officials payment purpose unlawfully influencing decisions actions respect subject matter agreement434 employee valeant affiliates shall authority give direction either written oral source dova pharmaceuticals inc 10q 11 8 2018relating making commitment dova agents third party violation terms provision agreement435 neither valeant dova shall undertake activity connection agreement violates applicable law436 valeants dovas material failure abide provisions section 43 shall deemed material breach agreement valeant dova case may subject terms section 122 hereof437 dova shall ensure patient assistance program used connection product services performed thereby connection product shall operated accordance applicable law notwithstanding immediately preceding sentence dova shall liability respect breach noncompliance applicable law relating patient assistance program used connection product extent caused act omission field force personnel act omission compliance terms agreement applicable law instructions dova438 dova shall ensure governmentinsured patients receive copay support dova respect product439 dova shall ensure donations interactions 501 c 3 charitable foundation provides copay assistance governmentinsured patients respect product full compliance applicable laws4310 term valeant becomes aware material violation failure comply applicable law terms agreement member field force personnel engaged detailing shall promptly later two 2 business days becomes aware notify dova violation promptly possible thereafter shall notify steps taken intends take remediate violation4311 compliance managers soon practicable later thirty 30 days effective date party shall appoint representative act compliance manager agreement routinely responsible advising party compliance matters suitable seniority relevant experience expertise compliance manager time time party may change compliance manager giving written notice party compliance managers shall serve key point contact parties compliancerelated matters compliance manager shall facilitate resolution compliance issue compliance manager party compliance managers use good faith efforts reach consensus compliance matters compliance managers reach consensus issue promptly issue shall submitted dispute resolution process described section 136 upon reasonable request dova time valeant shall deliver dova copies valeants compliance program policies compliance training materials applicable field force personnels promotion product expressly stated herein valeant shall required modify compliance policies practices connection compliancerelated provisions herein44 field force personnel training product materials441 training training materials promotional materials subject terms section 441 dova shall prepare control content product training materials field force personnel product training materials ii product marketing educational materials promotional materials product training materials promotional materials collectively product materials dova shall solely responsible ensuring product materials prepared approved compliance regulatory approval product product labeling applicable law approved dova content product materials shall provided dova valeant advance valeant activates allow valeant review content provide verbal feedback dova advance use product materials within receipt product materials valeant shall verbally provide dova comments proposed revisions product materials comments revisions dova shall reasonably consider long dova deems suggestions acceptable promotion product provided event extent dova reasonably believes changes compliance applicable law regulatory approval product applicable product labeling dova shall required incorporate suggestions valeant product materials event disagreement parties regarding feedback received valeant respect product materials dova shall right conclusively determine matter valeant provided comments dova product materials dova accepts comments revised dova shall provide valeant revised versions product materials review valeant accordance terms timelines section 441 valeant shall use product materials approved dova performance valeant activities agreement provided however valeant shall required use product materials approved valeant incorporated commentssource dova pharmaceuticals inc 10q 11 8 2018provided valeant nothing herein shall require valeant use product materials created prepared dova valeant reserves right use certain product materials content product materials shall modified changed valeant field force personnel time without prior written approval dova instance dova shall responsible costs expenses creation development product materials valeant shall responsible costs expense reproduction printing delivery product materials valeant parties coordinate production delivery product materials allow sufficient internal field force review time accommodate scheduled training meetings distribution field force personnel engaged detailing event dova incurs costs expenses valeant responsible section 441 dova may deduct amounts payments due section 63 shall include description thereof applicable report section 63 promptly effective date parties collaborate finalize product materials accordance section 441 soon reasonably practical b commencing promotional materials used calendar year 2019 remainder term valeant dova shall meet discuss content promotional materials order ensure promotional materials appropriately address messaging may desired target professionals specialty discussions may take place forum jsc dova shall good faith reasonably consider comments suggestions valeant regarding promotional materials c promptly effective date parties collaborate plan schedule training sales representatives mutually acceptable time date including launch meeting sales representatives mutually acceptable location dova lead initial training valeant shall cooperate reasonable requests dova order support training costs expenses launch meetin'"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def clean_text(text):\n",
    "    text = text.lower()\n",
    "    text = special_character_remover.sub(' ', text)\n",
    "    text = extra_symbol_remover.sub('', text)\n",
    "    text = ' '.join(word for word in text.split() if word not in STOPWORDS)\n",
    "    return text\n",
    "    \n",
    "df['Context'] = df['Context'].apply(clean_text)\n",
    "df['Context'][8]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "bcc6d600",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1605111\n"
     ]
    }
   ],
   "source": [
    "print(df['Context'].apply(lambda x: len(x.split(' '))).sum())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "ae5a94e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.model_selection import train_test_split\n",
    "X = df['Context']\n",
    "y = df['Label Name']\n",
    "X_train, X_test, y_train, y_test = train_test_split(X, y, test_size=0.2, random_state = 42)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "59dbdcbe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "((408,), (102,), (408,), (102,))"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "X_train.shape,X_test.shape,y_train.shape,y_test.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "33b67ce9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Accuracy is : 0.39215686274509803\n"
     ]
    }
   ],
   "source": [
    "from sklearn.linear_model import LogisticRegression\n",
    "from sklearn.pipeline import Pipeline\n",
    "from sklearn.feature_extraction.text import TfidfTransformer\n",
    "\n",
    "lr = Pipeline([('vect', CountVectorizer()),\n",
    "               ('tfidf', TfidfTransformer()),\n",
    "               ('clf', LogisticRegression()),\n",
    "              ])\n",
    "\n",
    "lr.fit(X_train,y_train)\n",
    "y_pred1 = lr.predict(X_test)\n",
    "\n",
    "print(f\"Accuracy is : {accuracy_score(y_pred1,y_test)}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2448ca13",
   "metadata": {},
   "source": [
    "# Bert Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "966248aa",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/hrishikeshkanojiya/.local/lib/python3.8/site-packages/tqdm/auto.py:22: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import torch\n",
    "from tqdm.notebook import tqdm\n",
    "from transformers import BertTokenizer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "679621ff",
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import BertForSequenceClassification"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "1017c4fa",
   "metadata": {},
   "outputs": [],
   "source": [
    "from torch.utils.data import TensorDataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "0c88a9bc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Distributor Agreement': 0,\n",
       " 'Promotion Agreement': 1,\n",
       " 'Supply Agreement': 2,\n",
       " 'Hosting Agreement': 3,\n",
       " 'Joint Venture Agreemen': 4,\n",
       " 'Endorsement Agreement': 5,\n",
       " 'Consulting Agreement': 6,\n",
       " 'Marketing Agreement': 7,\n",
       " 'Strategic Alliance Agreement': 8,\n",
       " 'Sponsorship Agreement': 9,\n",
       " 'Franchise Agreement': 10,\n",
       " 'IP Agreement': 11,\n",
       " 'Service Agreement': 12,\n",
       " 'Agency Agreement': 13,\n",
       " 'Maintenance Agreement': 14,\n",
       " 'License Agreement': 15,\n",
       " 'Cooperation Agreement': 16,\n",
       " 'Collaboration/Cooperation Agreement': 17,\n",
       " 'Reseller Agreement': 18,\n",
       " 'Outsourcing Agreement': 19,\n",
       " 'Co-Branding Agreement': 20,\n",
       " 'Affiliate Agreement': 21,\n",
       " 'Development Agreement': 22,\n",
       " 'Manufacturing Agreement': 23,\n",
       " 'Transportation Agreement': 24,\n",
       " 'Non-Compete/No-Solicit/Non-Disparagement Agreement': 25}"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "possible_labels = df['Label Name'].unique()\n",
    "\n",
    "label_dict = {}\n",
    "for index, possible_label in enumerate(possible_labels):\n",
    "    label_dict[possible_label] = index\n",
    "label_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "2800f9ef",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['label'] = df['Label Name'].replace(label_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "72884975",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label Name</th>\n",
       "      <th>title</th>\n",
       "      <th>Context</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Distributor Agreement</td>\n",
       "      <td>LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...</td>\n",
       "      <td>exhibit 106 distributor agreement distributor ...</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Promotion Agreement</td>\n",
       "      <td>WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...</td>\n",
       "      <td>exhibit 1026 confidential treatment requested ...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Supply Agreement</td>\n",
       "      <td>LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...</td>\n",
       "      <td>exhibit 1016 supply contract contract date buy...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Hosting Agreement</td>\n",
       "      <td>CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...</td>\n",
       "      <td>1 exhibit 103ion logo wwwioncom 5613949484 561...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Joint Venture Agreemen</td>\n",
       "      <td>NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT</td>\n",
       "      <td>exhibit 1joint filing agreementthe undersigned...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Endorsement Agreement</td>\n",
       "      <td>ADAMSGOLFINC_03_21_2005-EX-10.17-ENDORSEMENT A...</td>\n",
       "      <td>redacted copyconfidential treatment requestedc...</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Consulting Agreement</td>\n",
       "      <td>KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSU...</td>\n",
       "      <td>exhibit 1023 corporate address fannin south pr...</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Joint Venture Agreemen</td>\n",
       "      <td>VEONEER,INC_02_21_2020-EX-10.11-JOINT VENTURE ...</td>\n",
       "      <td>exhibit 1011amendment terminationofjoint ventu...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Promotion Agreement</td>\n",
       "      <td>DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_1...</td>\n",
       "      <td>exhibit 102___________________________________...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Marketing Agreement</td>\n",
       "      <td>PACIRA PHARMACEUTICALS, INC. - A_R STRATEGIC L...</td>\n",
       "      <td>exhibit 1013confidential materials omitted fil...</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Marketing Agreement</td>\n",
       "      <td>MetLife, Inc. - Remarketing Agreement</td>\n",
       "      <td>exhibit 991execution versionmetlife incseries ...</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Strategic Alliance Agreement</td>\n",
       "      <td>FTENETWORKS,INC_02_18_2016-EX-99.4-STRATEGIC A...</td>\n",
       "      <td>exhibit 994 strategic alliance agreement edgef...</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Sponsorship Agreement</td>\n",
       "      <td>DOMINIADVISORTRUST_02_18_2005-EX-99.(H)(2)-SPO...</td>\n",
       "      <td>exhibit h 2 sponsorship agreement sponsorship ...</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Franchise Agreement</td>\n",
       "      <td>PfHospitalityGroupInc_20150923_10-12G_EX-10.1_...</td>\n",
       "      <td>appendix c sample nondisclosure noncompetition...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>IP Agreement</td>\n",
       "      <td>CerenceInc_20191002_8-K_EX-10.4_11827494_EX-10...</td>\n",
       "      <td>exhibit 104intellectual property agreementby b...</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Endorsement Agreement</td>\n",
       "      <td>ThriventVariableInsuranceAccountB_20190701_N-6...</td>\n",
       "      <td>endorsementcontract number endorsementeffectiv...</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Supply Agreement</td>\n",
       "      <td>ReynoldsConsumerProductsInc_20191115_S-1_EX-10...</td>\n",
       "      <td>exhibit 1018master supply agreementmaster supp...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Service Agreement</td>\n",
       "      <td>IntegrityFunds_20200121_485BPOS_EX-99.E UNDR C...</td>\n",
       "      <td>distribution services agreement january 18 202...</td>\n",
       "      <td>12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>IP Agreement</td>\n",
       "      <td>PREMIERBIOMEDICALINC_05_14_2020-EX-10.2-INTELL...</td>\n",
       "      <td>exhibit 102 intellectual property agreement in...</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Strategic Alliance Agreement</td>\n",
       "      <td>SIBANNAC,INC_12_04_2017-EX-2.1-Strategic Allia...</td>\n",
       "      <td>exhibit 201 strategic alliance agreement agree...</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Label Name  \\\n",
       "0          Distributor Agreement   \n",
       "1            Promotion Agreement   \n",
       "2               Supply Agreement   \n",
       "3              Hosting Agreement   \n",
       "4         Joint Venture Agreemen   \n",
       "5          Endorsement Agreement   \n",
       "6           Consulting Agreement   \n",
       "7         Joint Venture Agreemen   \n",
       "8            Promotion Agreement   \n",
       "9            Marketing Agreement   \n",
       "10           Marketing Agreement   \n",
       "11  Strategic Alliance Agreement   \n",
       "12         Sponsorship Agreement   \n",
       "13           Franchise Agreement   \n",
       "14                  IP Agreement   \n",
       "15         Endorsement Agreement   \n",
       "16              Supply Agreement   \n",
       "17             Service Agreement   \n",
       "18                  IP Agreement   \n",
       "19  Strategic Alliance Agreement   \n",
       "\n",
       "                                                title  \\\n",
       "0   LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...   \n",
       "1   WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...   \n",
       "2   LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...   \n",
       "3   CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...   \n",
       "4    NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT   \n",
       "5   ADAMSGOLFINC_03_21_2005-EX-10.17-ENDORSEMENT A...   \n",
       "6   KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSU...   \n",
       "7   VEONEER,INC_02_21_2020-EX-10.11-JOINT VENTURE ...   \n",
       "8   DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_1...   \n",
       "9   PACIRA PHARMACEUTICALS, INC. - A_R STRATEGIC L...   \n",
       "10              MetLife, Inc. - Remarketing Agreement   \n",
       "11  FTENETWORKS,INC_02_18_2016-EX-99.4-STRATEGIC A...   \n",
       "12  DOMINIADVISORTRUST_02_18_2005-EX-99.(H)(2)-SPO...   \n",
       "13  PfHospitalityGroupInc_20150923_10-12G_EX-10.1_...   \n",
       "14  CerenceInc_20191002_8-K_EX-10.4_11827494_EX-10...   \n",
       "15  ThriventVariableInsuranceAccountB_20190701_N-6...   \n",
       "16  ReynoldsConsumerProductsInc_20191115_S-1_EX-10...   \n",
       "17  IntegrityFunds_20200121_485BPOS_EX-99.E UNDR C...   \n",
       "18  PREMIERBIOMEDICALINC_05_14_2020-EX-10.2-INTELL...   \n",
       "19  SIBANNAC,INC_12_04_2017-EX-2.1-Strategic Allia...   \n",
       "\n",
       "                                              Context  label  \n",
       "0   exhibit 106 distributor agreement distributor ...      0  \n",
       "1   exhibit 1026 confidential treatment requested ...      1  \n",
       "2   exhibit 1016 supply contract contract date buy...      2  \n",
       "3   1 exhibit 103ion logo wwwioncom 5613949484 561...      3  \n",
       "4   exhibit 1joint filing agreementthe undersigned...      4  \n",
       "5   redacted copyconfidential treatment requestedc...      5  \n",
       "6   exhibit 1023 corporate address fannin south pr...      6  \n",
       "7   exhibit 1011amendment terminationofjoint ventu...      4  \n",
       "8   exhibit 102___________________________________...      1  \n",
       "9   exhibit 1013confidential materials omitted fil...      7  \n",
       "10  exhibit 991execution versionmetlife incseries ...      7  \n",
       "11  exhibit 994 strategic alliance agreement edgef...      8  \n",
       "12  exhibit h 2 sponsorship agreement sponsorship ...      9  \n",
       "13  appendix c sample nondisclosure noncompetition...     10  \n",
       "14  exhibit 104intellectual property agreementby b...     11  \n",
       "15  endorsementcontract number endorsementeffectiv...      5  \n",
       "16  exhibit 1018master supply agreementmaster supp...      2  \n",
       "17  distribution services agreement january 18 202...     12  \n",
       "18  exhibit 102 intellectual property agreement in...     11  \n",
       "19  exhibit 201 strategic alliance agreement agree...      8  "
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "d0b42204",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>Context</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Label Name</th>\n",
       "      <th>label</th>\n",
       "      <th>data_type</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Affiliate Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">21</th>\n",
       "      <th>train</th>\n",
       "      <td>9</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Agency Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">13</th>\n",
       "      <th>train</th>\n",
       "      <td>11</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Co-Branding Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">20</th>\n",
       "      <th>train</th>\n",
       "      <td>19</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Collaboration/Cooperation Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">17</th>\n",
       "      <th>train</th>\n",
       "      <td>9</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Consulting Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">6</th>\n",
       "      <th>train</th>\n",
       "      <td>9</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Cooperation Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">16</th>\n",
       "      <th>train</th>\n",
       "      <td>13</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Development Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">22</th>\n",
       "      <th>train</th>\n",
       "      <td>25</td>\n",
       "      <td>25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Distributor Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">0</th>\n",
       "      <th>train</th>\n",
       "      <td>27</td>\n",
       "      <td>27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>5</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Endorsement Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">5</th>\n",
       "      <th>train</th>\n",
       "      <td>20</td>\n",
       "      <td>20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Franchise Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">10</th>\n",
       "      <th>train</th>\n",
       "      <td>13</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Hosting Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">3</th>\n",
       "      <th>train</th>\n",
       "      <td>17</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">IP Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">11</th>\n",
       "      <th>train</th>\n",
       "      <td>15</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Joint Venture Agreemen</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">4</th>\n",
       "      <th>train</th>\n",
       "      <td>20</td>\n",
       "      <td>20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">License Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">15</th>\n",
       "      <th>train</th>\n",
       "      <td>28</td>\n",
       "      <td>28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>5</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Maintenance Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">14</th>\n",
       "      <th>train</th>\n",
       "      <td>29</td>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>5</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Manufacturing Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">23</th>\n",
       "      <th>train</th>\n",
       "      <td>14</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Marketing Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">7</th>\n",
       "      <th>train</th>\n",
       "      <td>14</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Non-Compete/No-Solicit/Non-Disparagement Agreement</th>\n",
       "      <th>25</th>\n",
       "      <th>train</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Outsourcing Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">19</th>\n",
       "      <th>train</th>\n",
       "      <td>15</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Promotion Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">1</th>\n",
       "      <th>train</th>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Reseller Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">18</th>\n",
       "      <th>train</th>\n",
       "      <td>10</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Service Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">12</th>\n",
       "      <th>train</th>\n",
       "      <td>24</td>\n",
       "      <td>24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>4</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Sponsorship Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">9</th>\n",
       "      <th>train</th>\n",
       "      <td>26</td>\n",
       "      <td>26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>5</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Strategic Alliance Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">8</th>\n",
       "      <th>train</th>\n",
       "      <td>27</td>\n",
       "      <td>27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>5</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Supply Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">2</th>\n",
       "      <th>train</th>\n",
       "      <td>15</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>3</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"2\" valign=\"top\">Transportation Agreement</th>\n",
       "      <th rowspan=\"2\" valign=\"top\">24</th>\n",
       "      <th>train</th>\n",
       "      <td>11</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>val</th>\n",
       "      <td>2</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                    title  \\\n",
       "Label Name                                         label data_type          \n",
       "Affiliate Agreement                                21    train          9   \n",
       "                                                         val            1   \n",
       "Agency Agreement                                   13    train         11   \n",
       "                                                         val            2   \n",
       "Co-Branding Agreement                              20    train         19   \n",
       "                                                         val            3   \n",
       "Collaboration/Cooperation Agreement                17    train          9   \n",
       "                                                         val            2   \n",
       "Consulting Agreement                               6     train          9   \n",
       "                                                         val            2   \n",
       "Cooperation Agreement                              16    train         13   \n",
       "                                                         val            2   \n",
       "Development Agreement                              22    train         25   \n",
       "                                                         val            4   \n",
       "Distributor Agreement                              0     train         27   \n",
       "                                                         val            5   \n",
       "Endorsement Agreement                              5     train         20   \n",
       "                                                         val            4   \n",
       "Franchise Agreement                                10    train         13   \n",
       "                                                         val            2   \n",
       "Hosting Agreement                                  3     train         17   \n",
       "                                                         val            3   \n",
       "IP Agreement                                       11    train         15   \n",
       "                                                         val            2   \n",
       "Joint Venture Agreemen                             4     train         20   \n",
       "                                                         val            3   \n",
       "License Agreement                                  15    train         28   \n",
       "                                                         val            5   \n",
       "Maintenance Agreement                              14    train         29   \n",
       "                                                         val            5   \n",
       "Manufacturing Agreement                            23    train         14   \n",
       "                                                         val            3   \n",
       "Marketing Agreement                                7     train         14   \n",
       "                                                         val            3   \n",
       "Non-Compete/No-Solicit/Non-Disparagement Agreement 25    train          3   \n",
       "Outsourcing Agreement                              19    train         15   \n",
       "                                                         val            3   \n",
       "Promotion Agreement                                1     train         10   \n",
       "                                                         val            2   \n",
       "Reseller Agreement                                 18    train         10   \n",
       "                                                         val            2   \n",
       "Service Agreement                                  12    train         24   \n",
       "                                                         val            4   \n",
       "Sponsorship Agreement                              9     train         26   \n",
       "                                                         val            5   \n",
       "Strategic Alliance Agreement                       8     train         27   \n",
       "                                                         val            5   \n",
       "Supply Agreement                                   2     train         15   \n",
       "                                                         val            3   \n",
       "Transportation Agreement                           24    train         11   \n",
       "                                                         val            2   \n",
       "\n",
       "                                                                    Context  \n",
       "Label Name                                         label data_type           \n",
       "Affiliate Agreement                                21    train            9  \n",
       "                                                         val              1  \n",
       "Agency Agreement                                   13    train           11  \n",
       "                                                         val              2  \n",
       "Co-Branding Agreement                              20    train           19  \n",
       "                                                         val              3  \n",
       "Collaboration/Cooperation Agreement                17    train            9  \n",
       "                                                         val              2  \n",
       "Consulting Agreement                               6     train            9  \n",
       "                                                         val              2  \n",
       "Cooperation Agreement                              16    train           13  \n",
       "                                                         val              2  \n",
       "Development Agreement                              22    train           25  \n",
       "                                                         val              4  \n",
       "Distributor Agreement                              0     train           27  \n",
       "                                                         val              5  \n",
       "Endorsement Agreement                              5     train           20  \n",
       "                                                         val              4  \n",
       "Franchise Agreement                                10    train           13  \n",
       "                                                         val              2  \n",
       "Hosting Agreement                                  3     train           17  \n",
       "                                                         val              3  \n",
       "IP Agreement                                       11    train           15  \n",
       "                                                         val              2  \n",
       "Joint Venture Agreemen                             4     train           20  \n",
       "                                                         val              3  \n",
       "License Agreement                                  15    train           28  \n",
       "                                                         val              5  \n",
       "Maintenance Agreement                              14    train           29  \n",
       "                                                         val              5  \n",
       "Manufacturing Agreement                            23    train           14  \n",
       "                                                         val              3  \n",
       "Marketing Agreement                                7     train           14  \n",
       "                                                         val              3  \n",
       "Non-Compete/No-Solicit/Non-Disparagement Agreement 25    train            3  \n",
       "Outsourcing Agreement                              19    train           15  \n",
       "                                                         val              3  \n",
       "Promotion Agreement                                1     train           10  \n",
       "                                                         val              2  \n",
       "Reseller Agreement                                 18    train           10  \n",
       "                                                         val              2  \n",
       "Service Agreement                                  12    train           24  \n",
       "                                                         val              4  \n",
       "Sponsorship Agreement                              9     train           26  \n",
       "                                                         val              5  \n",
       "Strategic Alliance Agreement                       8     train           27  \n",
       "                                                         val              5  \n",
       "Supply Agreement                                   2     train           15  \n",
       "                                                         val              3  \n",
       "Transportation Agreement                           24    train           11  \n",
       "                                                         val              2  "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "X_train, X_val, y_train, y_val = train_test_split(df.index.values, \n",
    "                                                  df.label.values, \n",
    "                                                  test_size=0.15, \n",
    "                                                  random_state=42, \n",
    "                                                  stratify=df.label.values)\n",
    "\n",
    "df['data_type'] = ['not_set']*df.shape[0]\n",
    "\n",
    "df.loc[X_train, 'data_type'] = 'train'\n",
    "df.loc[X_val, 'data_type'] = 'val'\n",
    "\n",
    "df.groupby(['Label Name', 'label', 'data_type']).count()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "593dae9c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label Name</th>\n",
       "      <th>title</th>\n",
       "      <th>Context</th>\n",
       "      <th>label</th>\n",
       "      <th>data_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Distributor Agreement</td>\n",
       "      <td>LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...</td>\n",
       "      <td>exhibit 106 distributor agreement distributor ...</td>\n",
       "      <td>0</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Promotion Agreement</td>\n",
       "      <td>WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...</td>\n",
       "      <td>exhibit 1026 confidential treatment requested ...</td>\n",
       "      <td>1</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Supply Agreement</td>\n",
       "      <td>LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...</td>\n",
       "      <td>exhibit 1016 supply contract contract date buy...</td>\n",
       "      <td>2</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Hosting Agreement</td>\n",
       "      <td>CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...</td>\n",
       "      <td>1 exhibit 103ion logo wwwioncom 5613949484 561...</td>\n",
       "      <td>3</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Joint Venture Agreemen</td>\n",
       "      <td>NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT</td>\n",
       "      <td>exhibit 1joint filing agreementthe undersigned...</td>\n",
       "      <td>4</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Endorsement Agreement</td>\n",
       "      <td>ADAMSGOLFINC_03_21_2005-EX-10.17-ENDORSEMENT A...</td>\n",
       "      <td>redacted copyconfidential treatment requestedc...</td>\n",
       "      <td>5</td>\n",
       "      <td>val</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Consulting Agreement</td>\n",
       "      <td>KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSU...</td>\n",
       "      <td>exhibit 1023 corporate address fannin south pr...</td>\n",
       "      <td>6</td>\n",
       "      <td>val</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Joint Venture Agreemen</td>\n",
       "      <td>VEONEER,INC_02_21_2020-EX-10.11-JOINT VENTURE ...</td>\n",
       "      <td>exhibit 1011amendment terminationofjoint ventu...</td>\n",
       "      <td>4</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Promotion Agreement</td>\n",
       "      <td>DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_1...</td>\n",
       "      <td>exhibit 102___________________________________...</td>\n",
       "      <td>1</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Marketing Agreement</td>\n",
       "      <td>PACIRA PHARMACEUTICALS, INC. - A_R STRATEGIC L...</td>\n",
       "      <td>exhibit 1013confidential materials omitted fil...</td>\n",
       "      <td>7</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Marketing Agreement</td>\n",
       "      <td>MetLife, Inc. - Remarketing Agreement</td>\n",
       "      <td>exhibit 991execution versionmetlife incseries ...</td>\n",
       "      <td>7</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Strategic Alliance Agreement</td>\n",
       "      <td>FTENETWORKS,INC_02_18_2016-EX-99.4-STRATEGIC A...</td>\n",
       "      <td>exhibit 994 strategic alliance agreement edgef...</td>\n",
       "      <td>8</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Sponsorship Agreement</td>\n",
       "      <td>DOMINIADVISORTRUST_02_18_2005-EX-99.(H)(2)-SPO...</td>\n",
       "      <td>exhibit h 2 sponsorship agreement sponsorship ...</td>\n",
       "      <td>9</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Franchise Agreement</td>\n",
       "      <td>PfHospitalityGroupInc_20150923_10-12G_EX-10.1_...</td>\n",
       "      <td>appendix c sample nondisclosure noncompetition...</td>\n",
       "      <td>10</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>IP Agreement</td>\n",
       "      <td>CerenceInc_20191002_8-K_EX-10.4_11827494_EX-10...</td>\n",
       "      <td>exhibit 104intellectual property agreementby b...</td>\n",
       "      <td>11</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Endorsement Agreement</td>\n",
       "      <td>ThriventVariableInsuranceAccountB_20190701_N-6...</td>\n",
       "      <td>endorsementcontract number endorsementeffectiv...</td>\n",
       "      <td>5</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Supply Agreement</td>\n",
       "      <td>ReynoldsConsumerProductsInc_20191115_S-1_EX-10...</td>\n",
       "      <td>exhibit 1018master supply agreementmaster supp...</td>\n",
       "      <td>2</td>\n",
       "      <td>val</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Service Agreement</td>\n",
       "      <td>IntegrityFunds_20200121_485BPOS_EX-99.E UNDR C...</td>\n",
       "      <td>distribution services agreement january 18 202...</td>\n",
       "      <td>12</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>IP Agreement</td>\n",
       "      <td>PREMIERBIOMEDICALINC_05_14_2020-EX-10.2-INTELL...</td>\n",
       "      <td>exhibit 102 intellectual property agreement in...</td>\n",
       "      <td>11</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Strategic Alliance Agreement</td>\n",
       "      <td>SIBANNAC,INC_12_04_2017-EX-2.1-Strategic Allia...</td>\n",
       "      <td>exhibit 201 strategic alliance agreement agree...</td>\n",
       "      <td>8</td>\n",
       "      <td>train</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      Label Name  \\\n",
       "0          Distributor Agreement   \n",
       "1            Promotion Agreement   \n",
       "2               Supply Agreement   \n",
       "3              Hosting Agreement   \n",
       "4         Joint Venture Agreemen   \n",
       "5          Endorsement Agreement   \n",
       "6           Consulting Agreement   \n",
       "7         Joint Venture Agreemen   \n",
       "8            Promotion Agreement   \n",
       "9            Marketing Agreement   \n",
       "10           Marketing Agreement   \n",
       "11  Strategic Alliance Agreement   \n",
       "12         Sponsorship Agreement   \n",
       "13           Franchise Agreement   \n",
       "14                  IP Agreement   \n",
       "15         Endorsement Agreement   \n",
       "16              Supply Agreement   \n",
       "17             Service Agreement   \n",
       "18                  IP Agreement   \n",
       "19  Strategic Alliance Agreement   \n",
       "\n",
       "                                                title  \\\n",
       "0   LIMEENERGYCO_09_09_1999-EX-10-DISTRIBUTOR AGRE...   \n",
       "1   WHITESMOKE,INC_11_08_2011-EX-10.26-PROMOTION A...   \n",
       "2   LohaCompanyltd_20191209_F-1_EX-10.16_11917878_...   \n",
       "3   CENTRACKINTERNATIONALINC_10_29_1999-EX-10.3-WE...   \n",
       "4    NELNETINC_04_08_2020-EX-1-JOINT FILING AGREEMENT   \n",
       "5   ADAMSGOLFINC_03_21_2005-EX-10.17-ENDORSEMENT A...   \n",
       "6   KIROMICBIOPHARMA,INC_05_11_2020-EX-10.23-CONSU...   \n",
       "7   VEONEER,INC_02_21_2020-EX-10.11-JOINT VENTURE ...   \n",
       "8   DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_1...   \n",
       "9   PACIRA PHARMACEUTICALS, INC. - A_R STRATEGIC L...   \n",
       "10              MetLife, Inc. - Remarketing Agreement   \n",
       "11  FTENETWORKS,INC_02_18_2016-EX-99.4-STRATEGIC A...   \n",
       "12  DOMINIADVISORTRUST_02_18_2005-EX-99.(H)(2)-SPO...   \n",
       "13  PfHospitalityGroupInc_20150923_10-12G_EX-10.1_...   \n",
       "14  CerenceInc_20191002_8-K_EX-10.4_11827494_EX-10...   \n",
       "15  ThriventVariableInsuranceAccountB_20190701_N-6...   \n",
       "16  ReynoldsConsumerProductsInc_20191115_S-1_EX-10...   \n",
       "17  IntegrityFunds_20200121_485BPOS_EX-99.E UNDR C...   \n",
       "18  PREMIERBIOMEDICALINC_05_14_2020-EX-10.2-INTELL...   \n",
       "19  SIBANNAC,INC_12_04_2017-EX-2.1-Strategic Allia...   \n",
       "\n",
       "                                              Context  label data_type  \n",
       "0   exhibit 106 distributor agreement distributor ...      0     train  \n",
       "1   exhibit 1026 confidential treatment requested ...      1     train  \n",
       "2   exhibit 1016 supply contract contract date buy...      2     train  \n",
       "3   1 exhibit 103ion logo wwwioncom 5613949484 561...      3     train  \n",
       "4   exhibit 1joint filing agreementthe undersigned...      4     train  \n",
       "5   redacted copyconfidential treatment requestedc...      5       val  \n",
       "6   exhibit 1023 corporate address fannin south pr...      6       val  \n",
       "7   exhibit 1011amendment terminationofjoint ventu...      4     train  \n",
       "8   exhibit 102___________________________________...      1     train  \n",
       "9   exhibit 1013confidential materials omitted fil...      7     train  \n",
       "10  exhibit 991execution versionmetlife incseries ...      7     train  \n",
       "11  exhibit 994 strategic alliance agreement edgef...      8     train  \n",
       "12  exhibit h 2 sponsorship agreement sponsorship ...      9     train  \n",
       "13  appendix c sample nondisclosure noncompetition...     10     train  \n",
       "14  exhibit 104intellectual property agreementby b...     11     train  \n",
       "15  endorsementcontract number endorsementeffectiv...      5     train  \n",
       "16  exhibit 1018master supply agreementmaster supp...      2       val  \n",
       "17  distribution services agreement january 18 202...     12     train  \n",
       "18  exhibit 102 intellectual property agreement in...     11     train  \n",
       "19  exhibit 201 strategic alliance agreement agree...      8     train  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(20)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "87345ded",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Downloading: 100%|████████████████████████████| 226k/226k [00:01<00:00, 204kB/s]\n",
      "Downloading: 100%|███████████████████████████| 28.0/28.0 [00:00<00:00, 22.0kB/s]\n",
      "Downloading: 100%|██████████████████████████████| 570/570 [00:00<00:00, 421kB/s]\n"
     ]
    }
   ],
   "source": [
    "tokenizer = BertTokenizer.from_pretrained('bert-base-uncased', \n",
    "                                          do_lower_case=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "cb7545e3",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Truncation was not explicitly activated but `max_length` is provided a specific value, please use `truncation=True` to explicitly truncate examples to max length. Defaulting to 'longest_first' truncation strategy. If you encode pairs of sequences (GLUE-style) with the tokenizer you can select this strategy more precisely by providing a specific strategy to `truncation`.\n",
      "/home/hrishikeshkanojiya/.local/lib/python3.8/site-packages/transformers/tokenization_utils_base.py:2271: FutureWarning: The `pad_to_max_length` argument is deprecated and will be removed in a future version, use `padding=True` or `padding='longest'` to pad to the longest sequence in the batch, or use `padding='max_length'` to pad to a max length. In this case, you can give a specific length with `max_length` (e.g. `max_length=45`) or leave max_length to None to pad to the maximal input size of the model (e.g. 512 for Bert).\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "encoded_data_train = tokenizer.batch_encode_plus(\n",
    "    df[df.data_type=='train'].Context.values, \n",
    "    add_special_tokens=True, \n",
    "    return_attention_mask=True, \n",
    "    pad_to_max_length=True, \n",
    "    max_length=256, \n",
    "    return_tensors='pt'\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "c848d376",
   "metadata": {},
   "outputs": [],
   "source": [
    "encoded_data_val = tokenizer.batch_encode_plus(\n",
    "    df[df.data_type=='val'].Context.values, \n",
    "    add_special_tokens=True, \n",
    "    return_attention_mask=True, \n",
    "    pad_to_max_length=True, \n",
    "    max_length=256, \n",
    "    return_tensors='pt'\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "3c802dd7",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_ids_train = encoded_data_train['input_ids']\n",
    "attention_masks_train = encoded_data_train['attention_mask']\n",
    "labels_train = torch.tensor(df[df.data_type=='train'].label.values)\n",
    "\n",
    "input_ids_val = encoded_data_val['input_ids']\n",
    "attention_masks_val = encoded_data_val['attention_mask']\n",
    "labels_val = torch.tensor(df[df.data_type=='val'].label.values)\n",
    "\n",
    "dataset_train = TensorDataset(input_ids_train, attention_masks_train, labels_train)\n",
    "dataset_val = TensorDataset(input_ids_val, attention_masks_val, labels_val)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "7b2d8570",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at bert-base-uncased were not used when initializing BertForSequenceClassification: ['cls.predictions.transform.LayerNorm.bias', 'cls.predictions.transform.LayerNorm.weight', 'cls.predictions.bias', 'cls.predictions.transform.dense.bias', 'cls.seq_relationship.bias', 'cls.predictions.transform.dense.weight', 'cls.seq_relationship.weight', 'cls.predictions.decoder.weight']\n",
      "- This IS expected if you are initializing BertForSequenceClassification from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertForSequenceClassification from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
      "Some weights of BertForSequenceClassification were not initialized from the model checkpoint at bert-base-uncased and are newly initialized: ['classifier.weight', 'classifier.bias']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    }
   ],
   "source": [
    "model = BertForSequenceClassification.from_pretrained(\"bert-base-uncased\",\n",
    "                                                      num_labels=len(label_dict),\n",
    "                                                      output_attentions=False,\n",
    "                                                      output_hidden_states=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "4358de65",
   "metadata": {},
   "outputs": [],
   "source": [
    "from torch.utils.data import DataLoader, RandomSampler, SequentialSampler\n",
    "\n",
    "batch_size = 3\n",
    "\n",
    "dataloader_train = DataLoader(dataset_train, \n",
    "                              sampler=RandomSampler(dataset_train), \n",
    "                              batch_size=batch_size)\n",
    "\n",
    "dataloader_validation = DataLoader(dataset_val, \n",
    "                                   sampler=SequentialSampler(dataset_val), \n",
    "                                   batch_size=batch_size)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "id": "1b97f4e4",
   "metadata": {},
   "outputs": [],
   "source": [
    "from transformers import AdamW, get_linear_schedule_with_warmup\n",
    "\n",
    "optimizer = AdamW(model.parameters(),\n",
    "                  lr=1e-5, \n",
    "                  eps=1e-8)\n",
    "                  \n",
    "epochs = 5\n",
    "\n",
    "scheduler = get_linear_schedule_with_warmup(optimizer, \n",
    "                                            num_warmup_steps=0,\n",
    "                                            num_training_steps=len(dataloader_train)*epochs)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "id": "c97702ea",
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics import f1_score\n",
    "\n",
    "def f1_score_func(preds, labels):\n",
    "    preds_flat = np.argmax(preds, axis=1).flatten()\n",
    "    labels_flat = labels.flatten()\n",
    "    return f1_score(labels_flat, preds_flat, average='weighted')\n",
    "\n",
    "def accuracy_per_class(preds, labels):\n",
    "    label_dict_inverse = {v: k for k, v in label_dict.items()}\n",
    "    \n",
    "    preds_flat = np.argmax(preds, axis=1).flatten()\n",
    "    labels_flat = labels.flatten()\n",
    "\n",
    "    for label in np.unique(labels_flat):\n",
    "        y_preds = preds_flat[labels_flat==label]\n",
    "        y_true = labels_flat[labels_flat==label]\n",
    "        print(f'Class: {label_dict_inverse[label]}')\n",
    "        print(f'Accuracy: {len(y_preds[y_preds==label])}/{len(y_true)}\\n')"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "03d675e0",
   "metadata": {},
   "source": [
    "# nlp"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "840a7c78",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
